{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:27:38Z","timestamp":1792704458199,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.esmoop.2024.104098","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T06:32:43Z","timestamp":1736058763000},"page":"104098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Exploring novel therapeutic targets in small bowel adenocarcinoma: insights from claudin 18.2, nectin-4, and HER3 expression analysis"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8946-6970","authenticated-orcid":false,"given":"H.","family":"Fujii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8922-5227","authenticated-orcid":false,"given":"H.","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1343-1419","authenticated-orcid":false,"given":"H.","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3623-6691","authenticated-orcid":false,"given":"T.","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1733-5072","authenticated-orcid":false,"given":"K.","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2024.104098_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2024.104098_bib2","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/sj.bjc.6690541","article-title":"Descriptive epidemiology of small intestinal malignancies: the German Cancer Registry experience","volume":"80","author":"Stang","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2024.104098_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/SLA.0b013e31818e4641","article-title":"Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years","volume":"249","author":"Bilimoria","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.esmoop.2024.104098_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.dld.2013.04.013","article-title":"Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment","volume":"46","author":"Aparicio","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.esmoop.2024.104098_bib5","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/cncr.20404","article-title":"Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients","volume":"101","author":"Dabaja","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2024.104098_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.14694\/EdBook_AM.2013.33.189","article-title":"Rare but real: management of small bowel adenocarcinoma","volume":"33","author":"Overman","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.esmoop.2024.104098_bib7","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2008.19.7145","article-title":"Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater","volume":"27","author":"Overman","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.104098_bib8","first-page":"689","article-title":"Efficacy of the FOLFOX\/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China","volume":"16","author":"Zhang","year":"2011","journal-title":"J\u00a0BUON"},{"key":"10.1016\/j.esmoop.2024.104098_bib9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CAD.0b013e328350dd0d","article-title":"A\u00a0phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma","volume":"23","author":"Xiang","year":"2012","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.esmoop.2024.104098_bib10","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1002\/cncr.30766","article-title":"North Central Cancer Treatment Group N0543 (Alliance): a phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma","volume":"123","author":"McWilliams","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2024.104098_bib11","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/cncr.25614","article-title":"Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study","volume":"117","author":"Zaanan","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2024.104098_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/annonc\/mdx688","article-title":"Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer","volume":"29","author":"Overman","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.104098_bib13","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jamaoncol.2017.1051","article-title":"Genomic profiling of small-bowel adenocarcinoma","volume":"3","author":"Schrock","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.104098_bib14","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/cncr.30445","article-title":"Bevacizumab combined with\u00a0capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: a single-center, open-label, phase 2 study","volume":"123","author":"Gulhati","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2024.104098_bib15","doi-asserted-by":"crossref","first-page":"277-e26","DOI":"10.1634\/theoncologist.2017-0568","article-title":"Phase II study of panitumumab in RAS wild-type metastatic adenocarcinoma of small bowel or ampulla of Vater","volume":"23","author":"Gulhati","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2024.104098_bib16","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1158\/1078-0432.CCR-21-0159","article-title":"ZEBRA: a multicenter phase II study of pembrolizumab in patients with advanced small-bowel adenocarcinoma","volume":"27","author":"Pedersen","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.104098_bib17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-022-01362-9","article-title":"Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021","volume":"15","author":"Wu","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.esmoop.2024.104098_bib18","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2024.104098_bib19","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.104098_bib20","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.104098_bib21","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1200\/JCO.23.00882","article-title":"Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: a multicenter, phase I\/II trial","volume":"41","author":"Krop","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.104098_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.104098_bib23","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.3390\/ijms21155390","article-title":"Expression of Nectin-4 and PD-L1 in upper tract urothelial carcinoma","volume":"21","author":"Tomiyama","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.esmoop.2024.104098_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abk1538","article-title":"ARAF suppresses ERBB3 expression and\u00a0metastasis in a subset of lung cancers","volume":"8","author":"Mooz","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.esmoop.2024.104098_bib25","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2024.104098_bib26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of Nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.esmoop.2024.104098_bib27","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.104098_bib28","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.esmoop.2024.104098_bib29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.tibs.2018.09.008","article-title":"The claudins: from tight junctions to biological systems","volume":"44","author":"Tsukita","year":"2019","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.esmoop.2024.104098_bib30","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/path.1922","article-title":"Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype","volume":"208","author":"Sanada","year":"2006","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.esmoop.2024.104098_bib31","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.104098_bib32","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/his.14358","article-title":"Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy","volume":"79","author":"Iwaya","year":"2021","journal-title":"Histopathology"},{"key":"10.1016\/j.esmoop.2024.104098_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.154068","article-title":"Expression and prognostic analysis of CLDN18 and Claudin18.2 in lung adenocarcinoma","volume":"238","author":"Liu","year":"2022","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.esmoop.2024.104098_bib34","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00428-022-03393-6","article-title":"Claudin-18 expression in small bowel adenocarcinoma: a clinico-pathologic study","volume":"481","author":"Arpa","year":"2022","journal-title":"Virchows Arch"},{"key":"10.1016\/j.esmoop.2024.104098_bib35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00428-019-02624-7","article-title":"Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study","volume":"475","author":"Dottermusch","year":"2019","journal-title":"Virchows Arch"},{"key":"10.1016\/j.esmoop.2024.104098_bib36","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: a phase I study of single-agent enfortumab vedotin in patients with Nectin-4-positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.104098_bib37","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nature10639","article-title":"Adherens junction protein nectin-4 is the epithelial receptor for measles virus","volume":"480","author":"M\u00fchlebach","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2024.104098_bib38","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12935-019-0824-z","article-title":"Over-expression of Nectin-4 promotes progression of esophageal cancer and correlates with poor prognosis of the patients","volume":"19","author":"Deng","year":"2019","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.esmoop.2024.104098_bib39","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1158\/0008-5472.CAN-09-0016","article-title":"Identification of Nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer","volume":"69","author":"Takano","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2024.104098_bib40","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/annonc\/mdw678","article-title":"Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer","volume":"28","author":"M-Rabet","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.104098_bib41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1471-2407-7-73","article-title":"Nectin-4 is a new histological and serological tumor associated marker for breast cancer","volume":"7","author":"Fabre-Lafay","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2024.104098_bib42","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/djs501","article-title":"HER3 overexpression and survival in solid tumors: a meta-analysis","volume":"105","author":"Ocana","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2024.104098_bib43","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1158\/1078-0432.CCR-09-1218","article-title":"HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy","volume":"16","author":"Campbell","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.104098_bib44","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signaling network: receptor heterodimerization in development and cancer","volume":"19","author":"Olayioye","year":"2000","journal-title":"EMBO J"},{"key":"10.1016\/j.esmoop.2024.104098_bib45","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1186\/s12885-018-4917-1","article-title":"Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer","volume":"18","author":"Luhtala","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2024.104098_bib46","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12935-022-02844-z","article-title":"Changes in HER3 expression profiles between primary and recurrent gynecological cancers","volume":"23","author":"Kojima","year":"2023","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.esmoop.2024.104098_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.104098_bib48","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2024.104098_bib49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41416-024-02687-7","article-title":"Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases","volume":"131","author":"Thomas","year":"2024","journal-title":"Br J Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924018696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924018696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:56:00Z","timestamp":1737766560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924018696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2059702924018696"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104098","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring novel therapeutic targets in small bowel adenocarcinoma: insights from claudin 18.2, nectin-4, and HER3 expression analysis","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104098"}}